274 related articles for article (PubMed ID: 23948557)
1. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
Cao RY; Xiao JH; Cao B; Li S; Kumaki Y; Zhong W
Antivir Chem Chemother; 2014 Dec; 23(6):237-40. PubMed ID: 23948557
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969
[TBL] [Abstract][Full Text] [Related]
3. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
5. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
[TBL] [Abstract][Full Text] [Related]
6. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Farrukee R; Butler J; Reading PC; Hurt AC
Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
[TBL] [Abstract][Full Text] [Related]
7. The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
Ge Y; Chi Y; Min X; Zhao K; Wu B; Wu T; Zhu X; Shi Z; Zhu F; Cui L
Virology; 2019 Oct; 536():58-67. PubMed ID: 31400550
[TBL] [Abstract][Full Text] [Related]
8. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
[TBL] [Abstract][Full Text] [Related]
10. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
[TBL] [Abstract][Full Text] [Related]
11. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
Liu Q; Ma J; Strayer DR; Mitchell WM; Carter WA; Ma W; Richt JA
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):165-9. PubMed ID: 24350808
[TBL] [Abstract][Full Text] [Related]
12. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
[TBL] [Abstract][Full Text] [Related]
13. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
Qi Y; Fan H; Qi X; Zhu Z; Guo X; Chen Y; Ge Y; Zhao K; Wu T; Li Y; Shan Y; Zhou M; Shi Z; Wang H; Cui L
Virus Res; 2014 Jan; 179():119-24. PubMed ID: 24211668
[TBL] [Abstract][Full Text] [Related]
14. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan.
Lin PH; Chao TL; Kuo SW; Wang JT; Hung CC; Lin HC; Yang ZY; Ho SY; Chang CK; Huang MS; Chen HH; Chen YC; Lai HS; Chang SY; Chang SC; Yang PC
Clin Infect Dis; 2014 Jan; 58(2):242-6. PubMed ID: 24076969
[TBL] [Abstract][Full Text] [Related]
15. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
Hu Y; Lu S; Song Z; Wang W; Hao P; Li J; Zhang X; Yen HL; Shi B; Li T; Guan W; Xu L; Liu Y; Wang S; Zhang X; Tian D; Zhu Z; He J; Huang K; Chen H; Zheng L; Li X; Ping J; Kang B; Xi X; Zha L; Li Y; Zhang Z; Peiris M; Yuan Z
Lancet; 2013 Jun; 381(9885):2273-9. PubMed ID: 23726392
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Zhang Y; Gao H; Liang W; Tang L; Yang Y; Wu X; Yu L; Chen P; Zheng S; Ou H; Li L
BMC Infect Dis; 2016 Feb; 16():76. PubMed ID: 26864456
[TBL] [Abstract][Full Text] [Related]
17. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
19. Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus.
Mok CK; Chang SC; Chen GW; Lo YL; Chen SJ; Wu HS; Liu MT; Chang FY; Lin TY; Shih SR
J Microbiol Immunol Infect; 2015 Aug; 48(4):465-9. PubMed ID: 24388586
[TBL] [Abstract][Full Text] [Related]
20. Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013.
Gao HN; Yao HP; Liang WF; Wu XX; Wu HB; Wu NP; Yang SG; Zhang Q; Su KK; Guo J; Zheng SF; Zhu YX; Chen HL; Yuen KY; Li LJ
Int J Infect Dis; 2014 Dec; 29():254-8. PubMed ID: 25462187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
